Adults with asthma who began taking GLP-1 receptor agonists experienced nearly 40 percent fewer asthma attacks than peers on other medications, according to a recent observational study presented at the European Respiratory Society’s annual meeting.
Medical innovations frequently move beyond their initial indications, and glucagon-like peptide-1 receptor agonists are a prime example. These drugs now encompass weight management, cardiology, and sleep medicine, having originally served to address type 2 diabetes and obesity along with sleep apnea and heart disease.
In Plain English: The Clinical Takeaway
- What was studied: To assess respiratory health outcomes, investigators examined database records across four distinct studies involving roughly 20,000 individuals each who commenced treatment with either a sulfonylurea—a traditional diabetes medication—or a GLP-1.
- The core finding: Asthma patients taking a GLP-1 experienced roughly 40 percent fewer asthma attacks, while patients with chronic obstructive pulmonary disease (COPD) saw a 20 percent reduction in flare-ups.
- Current medical guidance: Doctors stress that these findings are observational and not yet peer-reviewed. Steroid inhalers remain the first-line treatment, and patients should not start GLP-1 receptor agonists specifically for lung conditions outside current prescribing guidance.
Unpacking the Data: Asthma, Obesity, and Airway Inflammation
According to the Centers for Disease Control and Prevention (CDC), nearly 39 percent of Americans with asthma also have obesity. Obesity is a significant risk factor for asthma, worse asthma symptoms, and poor asthma control. Excess fat tissue in the abdomen contains inflammatory cells that can produce chemicals called cytokines. These cytokines may spark inflammation throughout the body, including in the airways of people who may be genetically susceptible.
“Obesity and diabetes may contribute to airway inflammation, which in turn can cause worse asthma symptoms,” explains Jimmy Johannes, MD, a pulmonologist and critical care medicine specialist at MemorialCare Long Beach Medical Center in California, who was not involved in the new research. Because asthma is likewise an inflammation-driven condition, Boston-based Tufts Medical Center diabetes and lipid center co-director and Tufts Medicine endocrinologist Dr. Richard Siegel highlights that obesity-linked cytokine elevations might actively foster asthma development.
Imperial College London clinical associate professor and study co-author Dr. Chloe Bloom emphasizes that standard asthma therapies like inhaled steroids might exhibit reduced effectiveness among individuals struggling with both asthma and obesity. By addressing metabolic dysfunction, GLP-1 therapies may help bridge this therapeutic gap.
Evaluating the Observational Findings and Medication Comparisons
The research team reviewed patient data sourced from four separate investigations, each comprising roughly 20,000 subjects who began therapy using either a sulfonylurea—an older class of diabetes medications—or a GLP-1 receptor agonist. Patients taking semaglutide—marketed as Ozempic and Wegovy—demonstrated the strongest reduction in asthma attack frequency.
The analysis also evaluated older GLP-1 medications and observed more modest reductions in breathing attacks of any kind. The now-discontinued drug exenatide (Byetta) was linked to a 23 percent reduction in attacks and flares, while dulaglutide (Trulicity) showed a 12 percent decrease. Beyond asthma, adults suffering from chronic obstructive pulmonary disease (COPD)—an umbrella term for disorders that block airflow and make breathing difficult—experienced 20 percent fewer flare-ups while on a GLP-1.
| Medication Class / Specific Drug | Condition Evaluated | Observed Reduction in Attacks/Flare-ups |
|---|---|---|
| GLP-1 Receptor Agonists (Overall / Semaglutide focus) | Asthma | Nearly 40 percent fewer attacks |
| GLP-1 Receptor Agonists | COPD (Chronic Obstructive Pulmonary Disease) | 20 percent fewer flare-ups |
| Exenatide (Byetta – older GLP-1) | Attacks and flares | 23 percent reduction |
| Dulaglutide (Trulicity – older GLP-1) | Attacks and flares | 12 percent reduction |
Due to the study’s observational design, establishing direct cause and effect remains challenging; rather, the findings simply point toward an association connecting these drugs with a lower frequency of breathing incidents. Furthermore, the findings were presented at a medical congress and have not yet been peer-reviewed or published in a journal.
“We still need mechanistic studies and clinical trials to understand exactly how [GLP-1s] work and how much of the benefit is due to weight loss versus other effects,” Dr. Bloom notes. While the weight loss accompanying GLP-1 treatment could lower systemic and airway inflammation, scientists also highlight the presence of pulmonary GLP-1 receptors, prompting inquiries into whether these medications exert direct lung effects independent of shedding pounds.
Contraindications & When to Consult a Doctor
“People with asthma should not start GLP-1 receptor agonists specifically for their lung condition outside current prescribing guidance,” Dr. Bloom cautions. Standard therapies such as steroid inhalers, along with avoiding allergens and environmental triggers, optimal nutrition and exercise, remain important for asthma control. Inhalers and oral and injectable medications typically help with inflammation as well.
References
- Centers for Disease Control and Prevention (CDC). Obesity and Asthma Data and Statistics.
- European Respiratory Society (ERS). Annual Meeting Scientific Presentations on Metabolic Therapies and Airway Disease.
- Imperial College London. Clinical Research on Metabolic Disease and Respiratory Outcomes.
